title: Kinetics of aluminoxamine and feroxamine chelates in dialysis patients.
abstract: To achieve a rational basis for the use of deferoxamine (DFO) in aluminum (AL) -and iron (Fe)-overloaded uremic patients, important insights may be provided by the recently available micromethods to determine DFO and its metallochelates aluminoxamine (AlA) and feroxamine (FeA). With this procedure, AlA and FeA plasma kinetics were evaluated in a pilot study in 10 uremic patients during a whole week after a single DFO infusion performed during the first hour of the first standard bicarbonate hemodialysis (HD) of the week. Patients were divided into normal (n = 6) and high (n = 4) ferritin groups (1 and 2 respectively). Baseline Al concentrations were greater than 2 less than 6 in group 1 and less than 1.5 mumol/l in group 2. DFO was given at doses of 40, 20 and 10 mg/kg. AlA and FeA showed substantially different kinetics. AlA kinetics were similar in group 1 and 2: they reached their peak at the beginning of the 2nd HD, decreased during the 2nd and 3rd HD, and with the highest DFO dose still increased between the 2nd and 3rd HD. At similar pre-DFO Al values (greater than 2 less than 3.3 mumol/l), increased DFO doses produced increased AlA concentrations ranging from 95 to 40% of total plasma Al for all the week. At higher pre-DFO Al values (greater than 3.5 less than 6 mumol/l), even a DFO dose as low as 10 mg/kg was sufficient to form consistent AlA amounts (from 80 to 15% of total Al).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Nephrology, University of Torino, S. Giovanni-Molinette Hospital, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Canavese
authors.forename: L
authors.initials: L
authors.lastname: Gurioli
authors.forename: M
authors.initials: M
authors.lastname: D'Amicone
authors.forename: R
authors.initials: R
authors.lastname: Cardelli
authors.forename: F
authors.initials: F
authors.lastname: Caligaris
authors.forename: P
authors.initials: P
authors.lastname: Bongiorno
authors.forename: A
authors.initials: A
authors.lastname: Arnaud
authors.forename: G
authors.initials: G
authors.lastname: Mattiello
authors.forename: M
authors.initials: M
authors.lastname: Marchiori
mesh_terms: D000328:Adult; D000368:Aged; D000535:Aluminum / Q000097:blood; D002614:Chelating Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D003676:Deferoxamine / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000097:blood; D007700:Kinetics; D008875:Middle Aged; D009942:Organometallic Compounds / Q000097:blood* / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D014511:Uremia / Q000097:blood / Q000188:drug therapy / Q000628:therapy
chemical_list: D002614:Chelating Agents; D009942:Organometallic Compounds; C049544:aluminoxamine; D000535:Aluminum; D007501:Iron; D003676:Deferoxamine